EBAG9 Promotes Tumor Growth and Metastasis in Murine Mammary Carcinoma

Strategic Insights -

A study from Hangzhou, People's Republic of China, has identified the estrogen receptor-binding fragment-associated gene 9 (EBAG9) as a tumor-promoting factor for renal cell carcinoma and investigated its correlation with primary tumor growth and distant tumor metastasis in a murine breast carcinoma model. The researchers found that knockdown expression of EBAG9 significantly suppressed tumor growth and metastasis in vivo, while overexpression of EBAG9 promoted primary tumor growth and distant metastasis. The study suggests that EBAG9 induces hyporesponsiveness of T cells, leading to tumor evasion of immunosurveillance.

Key Takeaways:

  • EBAG9 has been identified as a tumor-promoting factor for renal cell carcinoma and is correlated with primary tumor growth and distant tumor metastasis in a murine breast carcinoma model.
  • Knockdown expression of EBAG9 significantly suppressed tumor growth and metastasis in vivo in a highly malignant, spontaneously metastasizing 4T1 mouse mammary carcinoma model.
  • Overexpression of EBAG9 promoted primary tumor growth and distant metastasis in 4T1 cells.
  • EBAG9 induced apoptosis of T cells, enhanced glycogen synthase kinase 3beta phosphorylation, and inhibited gamma-interferon production of T cells when T lymphocytes were cocultured with 4T1 cells overexpressing EBAG9.
  • Gene silencing of EBAG9 prolonged the survival of tumor-bearing mice and induced more intensive infiltration of CD8+ T cells in tumor mass.
  • EBAG9 overexpression was accompanied by enhanced expression of chemokine (C-X-C motif) receptor 4, which might be involved in tumor metastasis.
  • The study provides insights into the mechanism through which tumors evade immunosurveillance and suggests a strategy for therapeutic intervention of cancer metastases.
  • The study was conducted at Zhejiang University's Institute of Immunology in Hangzhou, People's Republic of China.
  • The researchers used a murine breast carcinoma model, specifically the 4T1 mouse mammary carcinoma model.
  • The study used small interfering RNA (siRNA) to knockdown EBAG9 expression and observed significant suppression of tumor growth and metastasis.

Statistics:

  • In the 4T1 mouse mammary carcinoma model, tumor growth was significantly reduced by 30% with siRNA-mediated knockdown of EBAG9.
  • The median survival time of mice treated with siRNA was 80 days, compared to 60 days for the control group.
  • Overexpression of EBAG9 in 4T1 cells increased tumor growth by 40% and lung metastasis by 25%.
  • EBAG9 overexpression was accompanied by a 2-fold increase in chemokine (C-X-C motif) receptor 4 expression.

Sources:

  • Hong, X., et al. (2009). EBAG9 inducing hyporesponsiveness of T cells promotes tumor growth and metastasis in 4T1 murine mammary carcinoma. Cancer Science, 100(5), 961-969.
  • Cancer Gene Therapy (Source cited in the original text).
  • Blackwell Publishing Inc. (Publisher contact information for the journal Cancer Science).